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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a complex condition with pulmonary and extra-
pulmonary manifestations. This study describes the heterogeneity of COPD in a large and well characterised and
controlled COPD cohort (ECLIPSE).
Methods: We studied 2164 clinically stable COPD patients, 337 smokers with normal lung function and 245 never
smokers. In these individuals, we measured clinical parameters, nutritional status, spirometry, exercise tolerance, and
amount of emphysema by computed tomography.
Results: COPD patients were slightly older than controls and had more pack years of smoking than smokers with
normal lung function. Co-morbidities were more prevalent in COPD patients than in controls, and occurred to the
same extent irrespective of the GOLD stage. The severity of airflow limitation in COPD patients was poorly related
to the degree of breathlessness, health status, presence of co-morbidity, exercise capacity and number of
exacerbations reported in the year before the study. The distribution of these variables within each GOLD stage
was wide. Even in subjects with severe airflow obstruction, a substantial proportion did not report symptoms,
exacerbations or exercise limitation. The amount of emphysema increased with GOLD severity. The prevalence of
bronchiectasis was low (4%) but also increased with GOLD stage. Some gender differences were also identified.
Conclusions: The clinical manifestations of COPD are highly variable and the degree of airflow limitation does not
capture the heterogeneity of the disease.
Background
Chronic obstructive pulmonary disease (COPD) is
defined by the presence of poorly reversible airflow lim-
itation [1]. Yet, COPD is a complex, multi-component,
heterogeneous disease, whose clinical, functional and
radiological presentation varies greatly from patient to
patient despite having a similar degree of airflow limita-
tion [1-3]. Unfortunately, the prevalence, distribution
and inter-relationships of the main clinical, functional
and radiological manifestations of the disease in a large,
well-characterised and controlled population of patients
are lacking.
Evaluation of COPD Longitudinally to Identify Predic-
tive Surrogate Endpoints (ECLIPSE) is a large observa-
tional study of COPD patients and controls conducted at
46 centres in 12 countries aimed at defining COPD phe-
notypes and identifying biomarkers and/or genetic para-
meters that help to predict disease progression [4].
ECLIPSE, therefore, offers a unique opportunity to charac-
terise the heterogeneity of COPD. To this end, we present
herein the cross-sectional analysis of the data collected at
recruitment in ECLIPSE. Specifically, we sought: (1) to
characterise the heterogeneity of COPD as a whole (vs.
controls); (2) to explore the relationships (or lack of them)
of the main clinical, functional and radiological character-
istics of the disease; (3) to investigate the level of heteroge-
neity within each stage of disease severity, using either the
classification proposed by Global initiative for chronic
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the degree of airflow limitation [1], or the BODE index, a
multidimensional grading system that has proven better
than the FEV1 at predicting the risk of death from any
cause and from respiratory causes among COPD patients
[5]; and, finally, (4) because the prevalence of COPD in
women is increasing [6], we also analyzed potential gender
differences in the clinical, functional and radiological vari-
ables studied.
Methods
Study design
The study design of ECLIPSE (Clinicaltrials.gov identi-
fier NCT00292552; GSK study code SCO104960) has
been published previously [4]. Briefly, ECLIPSE is an
observational, longitudinal and controlled study where,
after the baseline visit, subjects are evaluated at 3
months, 6 months and then every 6 months for 3 years.
Results presented here represent the cross-sectional ana-
lysis of the data obtained at baseline. ECLIPSE complies
with the Declaration of Helsinki and Good Clinical
Practice Guidelines, and has been approved by the ethics
committees of the participating centres. All participants
provided written informed consent.
Population
Power calculation was based on precision of effect esti-
mates in COPD subgroups for rate of decline in FEV1
over 3 years (confidence interval width of at most 15
mL/year in rate of FEV1 decline). The sizes of the con-
trol groups were based on both the ability to detect a
difference of at least 16.5 mL/year rate of decline in
FEV1 between COPD patients and controls, and to
detect a 50% increase in exposure (required 5-7 COPD
patients per control) for any diagnostic test. Based upon
these calculations, we studied 2164 patients with COPD
(GOLD stage 2-4), 337 smoking controls and 245 non-
smoking controls (Figure 1). Inclusion criteria were as
follows [4]. COPD patients: (1) Male/female subjects
aged 40-75 years; (2) Baseline post-bronchodilator FEV1
< 80% of the reference value and FEV1/FVC ≤0.7; and,
(3) Current or ex-smokers with a smoking history of
≥10 pack-years. Smoker controls:( 1 )M a l e / f e m a l es u b -
jects aged 40-75 years, who are free from significant dis-
ease as determined by history, physical examination and
screening investigations; (2) Baseline post-bronchodilator
FEV1 > 85% of the reference value and FEV1/FVC > 0.7;
and, (3) Current or ex-smokers with a smoking history
≥10 pack-years. Non smoking controls: (1) Male/female
subjects aged 40-75 years, who are free from significant
disease as determined by history, physical examination
and screening investigations; (2) Baseline post-broncho-
dilator FEV1 > 85% of the reference value and FEV1/
FVC > 0.7; and, (3) Smoking history of <1 pack-year.
Besides, all participants: (4) signed and dated their writ-
ten informed consent prior to participation (which had
been approved by the Ethics Committees of all partici-
pating institutions); and, (5) had to have the ability to
comply with the requirements of the protocol and be
available for study visits over 3 years. Key exclusion cri-
teria were the presence of a respiratory disorder other
than COPD, other significant inflammatory diseases or a
reported COPD exacerbation within 4 weeks of enrol-
ment [4]. COPD patients were recruited from the outpa-
tient clinics of the participating centres (Figure 1).
Smoker and non-smoker controls were recruited
through site databases and other methods (advertise-
ments in local newspapers and television/radio stations)
where appropriate. Figure 2 presents the variability of
age (panel A), gender (panel B), smoking status (panel
C) and FEV1 (panel D) in the three groups of individuals
recruited into ECLIPSE (COPD patients, smokers and
non-smokers with normal lung function) by each of the
46 participating centres.
Measurements
The American Thoracic Society (ATS) respiratory ques-
tionnaire, the modified Medical Research Questionnaire
(mMRC) and the COPD-specific version of the St.
George’s Respiratory Questionnaire (SGRQ-C) [7] were
used to record clinical data. Exacerbations requiring
treatment with antibiotics, oral corticosteroids and/or
hospitalisation in the year prior to the study were also
recorded. Co-morbidities were self-reported using the
ATS-DLD-78 questionnaire. Nutritional status was
assessed by the body mass index (BMI) and fat-free
mass index (FFMI), the latter measured by bioelectrical
impedance [4]. Spirometry and the 6 minute walking
distance (6MWD) were performed according to interna-
tional guidelines [8,9]. Spirometric reference values were
those of the European Community for Coal and Steel
(ECCS) [10]. The BODE index was calculated according
to Celli et al [5].
All subjects underwent a low-dose computed tomo-
graphy (CT) scan of the chest acquired using multi-
detector-row CT scanners (GE Healthcare or Siemens
Healthcare) with a minimum of 4 rows, obtained in
supine position at suspended full inspiration without
administration of intravenous contrast. Exposure set-
tings were 120 kVp and 40 mAs and images were recon-
structed using 1.0 mm (Siemens) or 1.25 mm (GE)
contiguous slices and a low spatial frequency recon-
struction algorithm (GE: Standard; Siemens: b35f). CT
scanners were calibrated regularly using industry and
institutional standards. All of the CT scans were evalu-
ated at the central imaging unit at the University of
British Columbia, Vancouver, Canada. Quantitative
assessment of lung volumes and the percentage of lung
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as a representative of the presence of emphysema, was
performed using the software Pulmonary Workstation
2.0 (VIDA Diagnostics, Iowa City, IA, U.S.A.) [11]. Two
radiologists also determined the presence or absence of
bronchiectasis.
Statistical analysis
Results are shown as mean ± SD, frequency distribution
or proportion, as appropriate. Because none of the con-
tinuous variables were normally distributed (Kolmo-
gorov-Smirnov test), Kruskal-Wallis tests were used to
analyze the statistical significance of differences between
groups. Differences in categorical variables were assessed
using Cochran-Mantel-Haenszel tests. Correlations
between variables of interest were explored using Spear-
man’s Rho; p values less than 0.05 (two sided) were con-
sidered significant.
Role of the funding source
The study was sponsored by GlaxoSmithKline. A Steer-
ing Committee and a Scientific Committee comprising
in total ten academics and six representatives of the
sponsor developed the original study design and con-
cept, the plan for the current analyses, approved the
statistical plan, had full access to the data, and was
responsible for decisions with regard to publication. The
study sponsor did not place any restrictions with regard
to statements made in the final paper.
Results
COPD patients compared with controls
COPD patients were older than controls and had more
pack years of smoking than smokers with normal lung
function (Table 1). BMI was lower in patients with
COPD but differences were negligible in absolute values,
and the FFMI was not different between groups.
Patients with COPD were more symptomatic (according
to both the mMRC and SGRQ-C) than smokers with
normal lung function or never smokers (Table 1).
Co-morbidities were more prevalent in COPD; 38% of
patients with COPD had more than one co-morbidity
(23% in smokers with normal lung function and 16% in
non-smokers; p < 0.001). By definition, patients with
COPD had airflow limitation, whereas spirometry was
normal in the two control groups. On average, patients
Figure 1 Consort diagram.
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tion after inhalation of a bronchodilator than controls
(Table 1). The 6MWD in COPD was 369 ± 122 metres
and the BODE index 3.2 ± 2.1 units. The amount of
emphysema was significantly greater in COPD than in
controls. Bronchiectasis was observed in 4% of patients
with COPD but in none of the controls.
Heterogeneity of COPD by severity of airflow limitation
(GOLD)
Age and pack-years of smoking were similar in the dif-
ferent GOLD stages (Table 2) and neither was related to
the severity of airflow limitation (Figure 3). Symptoms
(mMRC and SGRQ-C) and reported exacerbations dur-
ing the previous year increased with disease severity,
whereas the proportion of current smokers, BMI, FFMI,
and the 6MWD decreased (Table 2). The frequency dis-
tribution of these variables within each GOLD category
was wide and unimodal, so no discrete subgroups could
be identified except for the fact that, within each GOLD
stage, a substantial proportion of patients did not com-
plain of symptoms, report exacerbations and/or exhibit
exercise limitation, even with severe disease (Figure 4).
In fact, while airflow limitation was significantly related
to breathlessness, health status, 6MWD and number of
exacerbations, there was considerable overlap between
GOLD stages (Figure 5). FEV1 reversibility decreased in
more severe disease. By contrast, co-morbidities
appeared to be independent of the degree of airflow lim-
itation (Table 2). The extent of emphysema (and the
prevalence of bronchiectasis) increased in proportion to
the GOLD stage (Table 2).
Heterogeneity of COPD by the BODE index
As shown in table 3, when results were stratified accord-
ing to the BODE index we found very similar results to
those observed when disease severity was graded accord-
ing to FEV1 (Table 2). Of note, age and pack-years of
smoking were again similar in the different BODE
scores. Symptoms (mMRC and SGRQ-C), airflow limita-
tion, number of reported exacerbations and the extent
of emphysema increased in proportion to BODE scores.
By contrast, BMI, FFMI, and exercise tolerance
decreased in proportion to BODE (Table 3).
Heterogeneity of COPD by gender
Within each GOLD category, age was similar between
males and females, but the latter had less smoking expo-
sure, lower BMI and FFMI, and reported more exacerba-
tions than males (Table 2). Cardiovascular co-morbidity
Figure 2 Variability of age (panel A), gender (panel B), smoking status (panel C) and FEV1 (panel D) in the three groups of individuals
recruited into ECLIPSE by the 46 participating centres.
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osteoporosis, inflammatory bowel disease, reflux and
depression requiring treatment were more reported more
often by females. There were no obvious differences in
t h ep r e v a l e n c ea n d / o rs e v e r i t yo fe m p h y s e m ab yg e n d e r
within each GOLD stage.
When gender differences were analysed by BODE
scores we found similar results. Age was similar between
males and females but that the latter had less smoking
exposure, lower BMI, FFMI and reported more exacer-
bations than males (Table 3). Reported symptoms and
health status was similar between genders. Interestingly,
spirometric indices at each BODE score were signifi-
cantly higher in females than males, but exercise toler-
ance was lower (Table 3). There were no obvious
gender differences by BODE in any of the radiological
variables analysed.
Heterogeneity of COPD by presence of chronic bronchitis
Table 4 presents the main clinical, functional and ima-
ging variables by GOLD stages according to the pre-
sence of chronic bronchitis, which was defined as per
the ATS questionnaire ("phlegm on most days for 3 or
more consecutive months during the year and trouble
with phlegm for 2 or more years”). We observed that
for each GOLD stage there was a significant preponder-
ance of current-smoker males among those with chronic
bronchitis, and that these patients had a poorer health
status than those without it (Table 4). No other clear
and consistent signal, including lung function and
Table 1 Mean ± SD, median (IQR), or proportion of the main anthropometric, clinical, functional and radiological
variables in the three groups of participants
COPD
(n = 2164)
Smoking controls
(n = 337)
Non-smoking controls
(n = 245)
p value
Clinical data
Age (years) 63.4 ± 7.1
a, b 55.4 ± 9.0 54.1 ± 9.0 < 0.001
Pack-years 48.6 ± 27.1
a, b 31.6 ± 21.5
b 0.2 ± 1.1 < 0.001
Current Smokers (%) 36
a 61 < 0.001
BMI (kg/m
2) 26.5 ± 5.7
b 26.8 ± 4.6 27.7 ± 5.4 0.004
FFMI (kg/m
2) 17.2 ± 2.8 17.1 ± 2.6 17.2 ± 2.7 0.842
mMRC Score 1.7 ± 1.1
a, b 0.2 ± 0.5
b 0.1 ± 0.3 < 0.001
SGRQ-C total score 50.1 ± 20.3
a, b 9.6 ± 12.3
b 4.8 ± 6.5 < 0.001
Number of exacerbations
c 0.9 ± 1.2
a, b 0.0 ± 0.1 0.0 ± 0.1 < 0.001
Heart trouble (%) 26
a, b 11 9 < 0.001
Heart attack (%) 9
a, b 3 1 < 0.001
Stroke (%) 4
d 2 1 0.018
Heart failure (%) 7
a, b 1 0 < 0.001
Arrhythmia (%) 12
a, d 5 7 < 0.001
Osteoporosis (%) 14
a, b 5 5 < 0.001
Diabetes (%) 10
b 7 5 0.003
Inflammatory bowel disease (%) 5
e 2 4 0.127
Peptic ulcer (%) 11
b 7
d 3 < 0.001
Reflux/heartburn (%) 27
d 29
d 19 0.031
Depression requiring tx (%) 17 15 14 0.506
Physiology
FEV1 (% predicted) 48.3 ± 15.8
a, b 108.6 ± 12.0
d 114.8 ± 13.9 < 0.001
FEV1/FVC (%) 44.8 ± 11.6
a, b 79.2 ± 5.2
d 81.1 ± 5.2 < 0.001
FEV1 reversibility (%) 10.7 ± 13.7
a, b 4.5 ± 5.8
d 2.7 ± 4.5 < 0.001
Distance walked (metres) 369 ± 122
BODE index 3.2 ± 2.1
Imaging
Emphysema (%) 17.6 ± 12.2
a, b 2.4 ± 3.1
b 4.1 ± 4.2 < 0.001
ap < 0.01 vs. smoking controls;
b< 0.01 vs. non-smoking controls;
c In the year prior to study
dp < 0.05 vs. non-smoking controls. entry.
ep < 0.05 vs. smoking
controls. Abbreviations: tx: treatment.
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Page 5 of 14Table 2 Main anthropometric, clinical, functional, and radiological variables in patients with COPD, stratified according to disease severity (GOLD) and
gender (mean ± SD, or proportion)
GOLD II GOLD III GOLD IV Comparing
Females
(n = 380)
Males
(n = 574)
p value Females
(n = 293)
Males
(n = 618)
p value Females
(n = 77)
Males
(n = 219)
p value GOLD stage within females GOLD stage within males
Clinical Data
Age (years) 63.0 ± 7.1 63.8 ± 7.3 0.043 62.6 ± 6.8 64.2 ± 7.0 < 0.001 60.7 ± 6.8 63.0 ± 7.0 0.012 0.034 0.075
Pack-years 41.1 ± 21.6 52.7 ± 31.4 < 0.001 42.6 ± 21.2 52.2 ± 27.0 < 0.001 41.1 ± 21.8 52.1 ± 28.4 < 0.001 0.547 0.640
Current smokers (%) 40 36 0.300 37 38 0.695 27 28 0.922 0.114 0.027
BMI (kg/m
2) 27.2 ± 6.4 27.5 ± 5.2 0.066 25.6 ± 6.0 26.4 ± 5.2 0.008 23.4 ± 6.4 25.5 ± 5.3 0.001 < 0.001 < 0.001
FFMI (kg/m
2) 16.2 ± 3.0 18.4 ± 2.6 < 0.001 15.4 ± 2.3 17.8 ± 2.6 < 0.001 14.8 ± 2.5 17.0 ± 2.4 < 0.001 < 0.001 < 0.001
mMRC score 1.4 ± 1.0 1.3 ± 1.0 0.645 1.9 ± 1.0 1.8 ± 1.0 0.050 2.3 ± 1.0 2.3 ± 1.0 0.975 < 0.001 < 0.001
SGRQ-C (total) 43.8 ± 20.2 41.6 ± 20.9 0.193 55.4 ± 18.0 53.4 ± 18.5 0.215 61.3 ± 15.6 61.8 ± 16.1 0.885 < 0.001 < 0.001
Number of exacerbations
a 0.8 ± 1.2 0.5 ± 0.9 < 0.001 1.2 ± 1.4 0.9 ± 1.3 0.005 1.5 ± 1.6 1.1 ± 1.4 0.044 < 0.001 < 0.001
Heart trouble (%) 19 30 < 0.001 17 30 < 0.001 22 27 0.343 0.632 0.687
Heart attack (%) 5 13 < 0.001 6 10 0.033 1 10 0.011 0.280 0.275
Stroke (%) 5 4 0.544 3 3 0.805 4 3 0.645 0.557 0.467
Heart failure (%) 4 9 0.002 3 8 0.003 11 9 0.597 0.007 0.884
Arrhythmia (%) 10 14 0.068 8 15 0.010 12 10 0.684 0.604 0.315
Osteoporosis (%) 28 5 < 0.001 32 7 < 0.001 29 7 < 0.001 0.601 0.415
Diabetes (%) 9 13 0.079 5 10 0.010 7 13 0.154 0.138 0.341
Inflammatory bowel disease (%) 9 4 0.003 6 3 0.016 12 4 0.019 0.156 0.308
Peptic ulcer (%) 10 12 0.283 10 11 0.728 11 7 0.239 0.959 0.082
Reflux/heartburn (%) 36 29 0.022 30 20 0.002 27 19 0.138 0.163 0.001
Depression requiring Tx (%) 23 11 < 0.001 32 10 < 0.001 26 12 0.004 0.036 0.846
Physiology
FEV1 (% predicted) 63.6 ± 8.2 62.8 ± 8.5 0.119 41.0 ± 5.8 40.0 ± 5.8 0.017 25.4 ± 3.2 24.5 ± 3.8 0.156 < 0.001 < 0.001
FEV1/FVC (%) 53.2 ± 8.8 52.5 ± 8.8 0.251 41.4 ± 8.9 40.0 ± 8.9 0.021 34.5 ± 8.0 31.2 ± 7.2 0.002 < 0.001 < 0.001
FEV1 reversibility (%) 10.6 ± 12.1 11.7 ± 13.0 0.056 10.3 ± 14.8 11.4 ± 14.5 0.316 5.5 ± 13.2 8.9 ± 14.0 0.037 0.002 0.007
6MWD (metres) 391 ± 113 415 ± 110 0.003 333 ± 119 366 ± 116 < 0.001 265 ± 118 297 ± 119 0.069 < 0.001 < 0.001
BODE Index 1.7 ± 1.4 1.6 ± 1.3 0.715 4.2 ± 1.6 3.8 ± 1.6 < 0.001 6.0 ± 1.6 5.6 ± 1.6 0.079 < 0.001 < 0.001
Imaging
Emphysema (%) 11.2 ± 9.5 12.7 ± 9.5 0.002 20.1 ± 11.7 20.0 ± 11.5 0.876 27.1 ± 13.7 28.6 ± 12.1 0.435 < 0.001 < 0.001
Bronchiectasis (%) < 1 2 0.057 3 6 0.044 9 7 0.468 < 0.001 0.003
a In the year prior to study entry.
Abbreviations: tx: treatment.
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4imaging variables, could be identified. Interestingly, the
frequency of reported exacerbations in the year before
recruitment was not different, at each GOLD stage,
between patients with and without chronic bronchitis
(Table 4).
Discussion
The results of this study confirm that COPD is a highly
heterogeneous disease [2,3] and provide a number of
observations that help to better delineate the complexity
of the disease. Of particular clinical relevance is the
observation that, within each GOLD stage (or BODE
score) of disease severity, symptoms, exercise tolerance,
the number of reported exacerbations and the preva-
lence of co-morbidities varied widely between patients,
and that even in patients with severe airflow obstruction
there were a substantial proportion of patients who did
not complain of symptoms, report exacerbations or
Figure 3 Relationship between age (panel A) and cumulative smoking exposure (panel B) at entry into the study and degree of
airflow limitation in patients with COPD. For further explanations see text.
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highlight the fact that FEV1 does not capture the com-
plexity of the disease and that clinical management of
patients with COPD needs to consider such complexity
rather than just spirometry alone. Other observations of
interest are discussed below.
COPD is characterised by an accelerated rate of
decline of FEV1 with age [1,12]. According to this
model, one might expect patients with severe COPD to
be older. This was not the case in ECLIPSE. In fact, we
did not find any relationship between age and FEV1.
Several explanations can be conceived for this, appar-
ently odd, observation. On the one hand, it should be
explicitly acknowledged that ECLIPSE is not a popula-
tion-based study. Hence, this observation can be due to
sampling bias, as compared to the epidemiological stu-
dies where most of the conflicting data comes from
[12]. Thus, factors relating to subject recruitment into
ECLIPSE may have resulted in similarly aged subjects
regardless of severity being enrolled. On the other hand,
the lack of relationship between age and severity of air-
flow limitation may also indicate that the ECLIPSE sub-
jects had previously had a wide range of lung function
decline, a possibility that would be perfectly in line with
the accepted pathophysiological models of COPD [1,12]
because it would suggest that, similarly to what has
been described in idiopathic pulmonary fibrosis [13] and
has been suggested in COPD [14,15], there are likely to
be rapid and slow decliners among the population of
COPD patients at large. This hypothesis will be tested
directly in the three-year longitudinal portion of
ECLIPSE.
Tobacco smoking is the main risk factor for COPD [1]
but it is well established that not all smokers develop
the disease as indicated by the identification of suscepti-
ble and non-susceptible smokers [12]. We observed that,
even among susceptible smokers (i.e. those smokers who
have already developed COPD), the relationship between
Figure 4 Frequency distribution of the breathlessness as assessed by the mMRC questionnaire (panel A), exercise capacity as assessed
by the 6MWD (panel B), reported exacerbations in the year before inclusion in the study (panel C), and health status assessed by
SGRQ-C (panel D) according to severity of disease. For further explanations see text.
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use, and airflow limitation is poor, albeit statistically sig-
nificant (Figure 3, panel B). This suggests that ‘suscept-
ibility’ is not a yes-no phenomenon. In fact, a range of
‘susceptibility levels’ was already suggested by Fletcher
and Peto in 1977 [12], and has been more recently con-
firmed in the Framingham offspring cohort [16], poten-
tially reflecting genetic differences or interactions with
other risk factors, such as nutrition or infections. How-
ever, similarly to what we discussed above in relation to
age, because ECLIPSE is not a population-based study, a
potential sampling bias cannot be excluded. Likewise,
smoking exposure was assessed by self-reported pack-
years, which is known to be a very crude estimate of
cumulative exposure to smoking.
Relief of symptoms and prevention of exacerbations
are two of the main goals of COPD management [1]. To
achieve them, therapy in COPD is guided broadly by the
severity of airflow limitation [1]. We confirmed [17] that
airflow limitation was poorly related to the degree of
breathlessness, health status, 6MWD and number of
exacerbations reported in the year before the study
(Figure 4). Furthermore, as discussed above, within each
category of airflow limitation, mMRC, SGRQ-C, 6MWD
and the number of reported exacerbations varied widely.
In fact, a substantial percentage of patients with severe
airflow obstruction did not complain of symptoms,
report exacerbations or show impaired exercise toler-
ance (Figure 4). These observations support the strategy
suggested by the UK National Institute for Clinical
Excellence (NICE) in that symptoms, exacerbations and
co-morbidities must also be included in the assessment
of the severity in any given patient, rather than just
spirometry alone, because this is likely to offer a more
appropriate way to direct therapy [18,19].
We found that the frequency of reported exacerba-
tions increased in parallel with airflow limitation but,
interestingly, exacerbations were not reported by a
Figure 5 Relationship between the severity of airflow limitation and breathlessness as assessed by the mMRC questionnaire (panel A),
exercise capacity as assessed by the 6MWD (panel B), reported exacerbations in the year before inclusion in the study (panel C), and
health status as assessed by SGRQ-C (panel D). For further explanations see text.
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Page 9 of 14Table 3 Main anthropometric, clinical, functional, and radiological variables in patients with COPD, stratified according to the BODE index and gender (mean
± SD or proportion)
BODE 0 1 2 BODE 3 4 BODE 5 6 BODE 7 8 9 10 Differences within
females
Differences within
males
Females Males p
value
Females Males p
value
Females Males p
value
Females Males p
value
Females Males
BODE Index 1.1 ± 0.8 1.3 ± 0.8 0.014 3.5 ± 0.5 3.4 ± 0.5 0.088 5.4 ± 0.5 5.4 ± 0.5 0.874 7.5 ± 0.8 7.5 ± 0.7 0.658 < 0.001 < 0.001
Clinical data
Age (years) 62.3 ±
7.0
63.5 ±
7.3
0.008 62.8 ±
6.8
63.6 ±
7.2
0.132 62.3 ±
7.0
64.9 ±
6.6
0.001 63.9 ±
7.1
63.9 ±
7.0
0.949 0.362 0.090
Pack years (n) 39.7 ±
20.5
51.0 ±
29.2
<
0.001
43.3 ±
22.2
50.6 ±
27.7
0.001 43.6 ±
22.9
55.7 ±
28.0
<
0.001
41.9 ±
17.8
57.8 ±
31.8
<
0.001
0.186 0.002
BMI (Kg/m
2) 26.4 ±
5.0
27.3 ±
4.5
0.001 26.1 ±
6.1
26.6 ±
5.5
0.162 26.4 ±
8.1
26.3 ±
6.1
0.596 23.8 ±
7.0
25.9 ±
6.0
0.017 0.006 < 0.001
FFMI (Kg/m
2) 15.9 ±
2.7
18.4 ±
2.3
<
0.001
15.5 ±
2.3
17.9 ±
2.7
<
0.001
15.8 ±
3.0
17.6 ±
2.9
<
0.001
14.9 ±
3.0
17.1 ±
2.4
<
0.001
0.001 < 0.001
MMRC score 0.9 ± 0.7 0.9 ± 0.7 0.893 1.8 ± 0.7 1.8 ± 0.8 0.443 2.6 ± 0.9 2.5 ± 0.8 0.619 3.1 ± 0.8 3.3 ± 0.6 0.051 < 0.001 < 0.001
SGRQ total score 38.0 ±
17.1
38.0 ±
18.7
0.961 54.1 ±
15.5
53.0 ±
16.1
0.541 63.1 ±
16.1
62.6 ±
14.6
0.809 70.2 ±
12.9
72.5 ±
13.2
0.352 < 0.001 < 0.001
Exacerbations
a(n) 0.6 ± 1.0 0.5 ± 0.9 0.006 1.1 ± 1.4 0.9 ± 1.3 0.152 1.5 ± 1.4 1.2 ± 1.5 0.006 1.6 ± 1.7 1.1 ± 1.2 0.276 < 0.001 < 0.001
Physiology
Post-BD FEV1 (%
ref).
62.1 ±
9.8
58.8 ±
11.7
<
0.001
46.6 ±
12.2
42.8 ±
12.1
0.001 37.9 ±
10.8
34.4 ±
9.4
0.003 32.6 ±
8.8
29.1 ±
8.5
0.022 < 0.001 < 0.001
Post-BD FEV/FVC
(%)
51.9 ±
9.1
49.7 ±
10.0
0.003 44.5 ±
10.4
41.9 ±
11.1
0.004 40.0 ±
10.6
36.9 ±
9.9
0.009 39.7 ±
9.9
35.0 ±
8.6
0.003 < 0.001 < 0.001
FEV1 reversibility
(%)
10.5 ±
12.5
11.3 ±
13.6
0.319 9.7 ±
14.8
12.2 ±
15.2
0.020 10.5 ±
14.4
10.6 ±
12.3
0.687 7.8 ±
12.8
8.3 ±
14.0
0.787 0.300 0.072
6MWD (metres) 432 ± 93 447 ± 94 0.013 349 ± 91 379 ± 95 <
0.001
269 ± 88 289 ± 84 0.015 164 ± 74 185 ± 67 0.084 < 0.001 < 0.001
Imaging
LAA 11.3 ±
9.9
13.8 ±
9.7
<
0.001
17.7 ±
11.1
19.0 ±
11.5
0.244 22.6 ±
13.2
23.6 ±
13.1
0.616 25.5 ±
13.6
28.9 ±
12.6
0.171 < 0.001 < 0.001
aIn the year prior to study entry.
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4Table 4 Main anthropometric, clinical, functional, and radiological variables in patients with COPD, stratified according to disease severity (GOLD) and the
presence or absence of chronic bronchitis (mean ± SD or proportion)
GOLD II GOLD III GOLD IV Comparing
Yes No p-value Yes No p-value Yes No p-value GOLD Stage within Yes GOLD Stage within No
Clinical data
N 294 660 337 574 118 178
Age (years) 62.6 (7.5) 63.8 (7.0) 0.018 63.2 (7.4) 64.0 (6.7) 0.183 62.0 (7.6) 62.7 (6.6) 0.698 0.335 0.043
Male (%) 193 (66%) 381 (58%) 0.021 258 (77%) 360 (63%) < 0.001 96 (81%) 123 (69%) 0.019 < 0.001 0.014
Pack-years 49.0 (29.3) 47.7 (28.1) 0.423 50.3 (27.3) 48.5 (24.6) 0.450 50.1 (28.9) 48.7 (26.1) 0.870 0.578 0.172
Current smokers (%) 153 (52%) 207 (31%) < 0.001 154 (46%) 187 (33%) < 0.001 44 (37%) 38 (21%) 0.003 0.021 0.015
BMI (kg/m
2) 26.7 (5.4) 27.7 (5.8) 0.007 26.0 (5.5) 26.3 (5.6) 0.415 24.3 (5.4) 25.4 (5.9) 0.140 < 0.001 < 0.001
FFMI (kg/m
2) 17.4 (2.7) 17.6 (3.0) 0.339 17.0 (2.5) 17.0 (2.9) 0.387 16.4 (2.6) 16.4 (2.6) 0.986 0.008 < 0.001
mMRC Score 1.5 (1.0) 1.3 (1.0) 0.002 1.8 (1.0) 1.8 (1.1) 0.861 2.4 (1.0) 2.3 (1.0) 0.739 < 0.001 < 0.001
SGRQ-C total score 50.3 (18.8) 38.9 (20.5) < 0.001 58.8 (17.6) 51.2 (18.2) < 0.001 65.0 (16.5) 59.4 (15.2) 0.010 < 0.001 < 0.001
Number of exacerbations
a 0.7 (1.1) 0.6 (1.0) 0.132 1.0 (1.2) 1.0 (1.4) 0.253 1.2 (1.6) 1.2 (1.3) 0.436 < 0.001 < 0.001
Physiology
FEV1 % Predicted 62.3 (8.8) 63.5 (8.2) 0.030 40.3 (5.7) 40.3 (5.9) 0.957 25.1 (3.4) 24.5 (3.8) 0.322 < 0.001 < 0.001
FEV1/FVC (%) 52.3 (9.0) 53.0 (8.7) 0.358 41.0 (9.4) 40.1 (8.6) 0.199 32.2 (8.6) 31.9 (6.8) 0.985 < 0.001 < 0.001
FEV1 reversibility (%) 10.8 (12.4) 11.4 (12.8) 0.222 11.2 (15.1) 10.9 (14.3) 0.826 8.2 (15.3) 7.8 (12.9) 0.866 0.070 0.001
6MWD (metres) 397 (118) 409 (109) 0.059 352 (113) 358 (121) 0.289 306 (125) 278 (115) 0.106 < 0.001 < 0.001
BODE Index 1.8 (1.4) 1.5 (1.3) < 0.001 4.0 (1.6) 3.9 (1.7) 0.430 5.7 (1.7) 5.8 (1.5) 0.730 < 0.001 < 0.001
Imaging
Emphysema (%) 12.3 (10.3) 12.0 (9.2) 0.854 19.1 (11.7) 20.5 (11.5) 0.082 28.3 (13.4) 28.1 (12.1) 0.822 < 0.001 < 0.001
Bronchiectasis (%) 3 (1%) 10 (2%) 0.644 22 (8%) 19 (4%) 0.006 7 (7%) 13 (8%) 0.797 0.001 < 0.001
aIn the year prior to study entry.
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4substantial proportion of patients, including those with
severe disease (Figure 4, panel C). Because this observa-
tion was based on patient recall, it may be subject to
both selection and recall bias. Observations in relation
to exacerbations, therefore, need to be confirmed pro-
spectively during follow-up in ECLIPSE. If confirmed, a
deeper understanding of why some patients with COPD
develop exacerbations, which may represent a phenotype
of COPD, whereas others do not (which may represent
another one) despite a similar degree of airflow limita-
tion may emerge. We could not confirm previous obser-
vations [20] that exacerbations of COPD were more
prevalent among patients with chronic bronchitis, at
e a c hG O L Ds t a g e( T a b l e4 ) .Y e t ,t h e s ea r es e l f - r e p o r t e d
exacerbations over the previous year, and this may be
subject to recall bias, so this finding will have to be con-
firmed or refuted during prospective follow up of these
patients.
In keeping with previous results [21], we found that
BMI and FFMI decreased progressively with increasing
airflow limitation, particularly in females (Table 2). Like-
wise, our results also confirm that co-morbidities occur
more frequently in patients with COPD than in controls
[22]. However, co-morbidities were largely independent
of the degree of airflow limitation and occurred similarly
in both moderate and severe disease. Because, ECLIPSE
is not a population-based study, we cannot exclude
some type of selection bias. However, the possibility that
co-morbidities may occur early during the course of the
disease raises important questions about their potential
pathogenic mechanisms [22] and highlights the clinical
importance of identifying (and treating) them if present
early in the course of the disease. We also found that
the extent of emphysema increased with GOLD stage,
as did the proportion of COPD patients with bronchiec-
tasis, although this proportion was small and lower than
that reported previously [23].
We identified several, potentially relevant, gender dif-
ferences. Interestingly, females had less smoking expo-
sure for the same degree of airflow limitation (Table 2)
or BODE score (Table 3), suggesting that women are
more susceptible to tobacco smoke. This observation
supports previous studies [24]. Also in keeping with pre-
vious reports [25], we found that women reported more
exacerbations than males for the same GOLD stage
(Table 2). Finally, females with COPD appeared particu-
larly susceptible to osteoporosis, inflammatory bowel
disease, reflux and depression requiring treatment rela-
tive to males, but less so with respect to cardiovascular
co-morbidity and diabetes (Table 2).
The main strength of our study is the large sample
size of patients (and controls) included, as well as their
careful clinical and functional characterisation thus
allowing the study of relationships between clinical,
functional, and radiological variables. The size of
ECLIPSE permits more accurate estimates of the var-
iance observed in a number of key parameters used to
assess COPD patients. While ECLIPSE is not a popula-
tion-based sample, recruitment was very similar to that
in other clinical trials and variability between centres
was minor (Figure 2). Thus, the data generated in
ECLIPSE will be helpful in estimating sample sizes in
future clinical studies. Our study, however, has some
limitations. First, COPD patients were older than con-
trols and had a history of more intense smoking expo-
sure than the group of smokers with normal lung
function. This may limit some of the comparisons
between patients and controls, but it is not relevant for
those analyses that include COPD patients only. Second,
many patients were recruited from populations receiving
care at the participating hospitals. Thus, the population
studied here may not be a true reflection of the COPD
patients regularly seen in primary care.
Conclusions
In summary, our results help to better delineate the het-
erogeneity and complexity of COPD by describing the
relationships (or lack thereof) between a number of
important clinical, functional, and radiological domains
of the disease. Of potential particular relevance is our
finding that the current GOLD classification of disease
severity, based upon the degree of airflow limitation, is a
poor predictor of other features of COPD. This observa-
tion is in keeping with recent observations by Burgel et
al using principal component analysis and cluster analy-
sis in a cohort of COPD subjects recruited in a French
multicentre study [26]. The clinical utility of the sub-
groups identified in any cross-sectional analysis, how-
ever, needs to be validated longitudinally against
clinically relevant outcomes [27]. The longitudinal analy-
sis of the follow-up data of the patients included in the
ECLIPSE study should hopefully allow these goals to be
achieved and, with them, a better understanding of the
complexity of the disease and potential clinical relevance
of the identified phenotypes.
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